Sivelestat

• Description:

  Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19[1][2][3][4].

• Product Name Alternative:

  EI546; LY544349; ONO5046

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Elastase; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sivelestat.html

• Purity:

  99.34

• Solubility:

  DMSO : ≥ 100 mg/mL|Ethanol : 3.03 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C)C(OC1=CC=C(S(=O)(NC2=CC=CC=C2C(NCC(O)=O)=O)=O)C=C1)=O

• Molecular Formula:

  C20H22N2O7S

• Molecular Weight:

  434.46

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177 (2) :814-20.|[2]Yuichiro Toda, et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med. 2007 Feb;19 (2) :237-43.|[3]Tomoharu Kono, et al. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem. 2008 Apr;311 (1-2) :87-92.|[4]Adeleh Sahebnasagh, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Aug 28.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Biofabrication. 2021 Apr 8;13 (3) :10.1088/1758-5090/abe1cf.|Brain Behav Immun. 2024 Jun 12:120:403-412.|Burns Trauma. 2021 Sep 17:9:tkab030.|Cancers (Basel) . 2022 Jan 20;14 (3) :515.|Cell Biosci. 2022 Jul 22;12 (1) :114.|Ecotoxicol Environ Saf. 2023 Dec:268:115694.|Elife. 2022 Mar 23:11:e77444.|Exp Mol Med. 2024 Dec;56 (12) :2602-2616.|Exp Mol Med. 2025 Sep;57 (9) :2067-2082.|FASEB J. 2024 Dec 15;38 (23) :e70238.|Heliyon. 2024 Oct 5;10 (19) :e38895.|Int Immunopharmacol. 2025 Jul 31:163:115276.|J Cell Mol Med. 2022 Apr;26 (7) :2089-2103.|J Exp Med. 2023 Sep 4;220 (9) :e20221751.|J Infect Dis. 2024 May 15;229 (5) :1352-1365.|J Tissue Eng. 2025 Aug 19:16:20417314251348038.|Nat Commun. 2025 Feb 5;16 (1) :1378.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|PLoS One. 2025 Nov 6;20 (11) :e0336333.|Res Sq. 2024 Jul 30.|Res Sq. 2025 May 08.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2023 Dec 11.|J Hepatocell Carcinoma. 2021 May 20:8:451-465.|J Neuroinflammation. 2025 Aug 26;22 (1) :206.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Oxid Med Cell Longev. 2019 Nov 23;2019:7323986.

• CAS Number:

  [127373-66-4]